Literature DB >> 1704804

Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

P D Emanuel1, L J Bates, R P Castleberry, R J Gualtieri, K S Zuckerman.   

Abstract

Juvenile chronic myelogenous leukemia (JCML) is a good model for the study of myeloproliferation because JCML hematopoietic progenitor cells grow in vitro at very low cell densities without the addition of exogenous stimulus. Previous studies have demonstrated that this proliferation is dependent on granulocyte-macrophage colony-stimulating factor (GM-CSF), and that removal of monocytes from the cell population before culture eliminates this "spontaneous" myeloproliferation, suggesting a paracrine role of monocyte stimulation. However, subsequent studies have shown that increased GM-CSF production from the JCML monocytes is not a consistent finding and therefore not a plausible sole mechanism. In examining hematopoietic growth factor dose-response curves, both JCML GM and erythroid nonadherent progenitor cell populations displayed a marked and selective hypersensitivity to GM-CSF. Responses to interleukin-3 and G-CSF were identical to control dose-response curves. This is the first demonstration of a myeloid leukemia in which hypersensitivity to a specific growth factor appears to be involved in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1704804

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  A case of congenital leukemia with monosomy 7.

Authors:  T Shitara; N Suetake; S Yugami; M Sotomatu; Y Oshima; H Ijima; T Kuroume; S Nakazawa
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

3.  IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.

Authors:  Stephane Wong; Jami McLaughlin; Donghui Cheng; Kevin Shannon; Lorraine Robb; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-19       Impact factor: 11.205

4.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.

Authors:  Julie E Niemela; Lianghao Lu; Thomas A Fleisher; Joie Davis; Iusta Caminha; Marc Natter; Laurel A Beer; Kennichi C Dowdell; Stefania Pittaluga; Mark Raffeld; V Koneti Rao; João B Oliveira
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

5.  NF1 inactivation in adult acute myelogenous leukemia.

Authors:  Brian Parkin; Peter Ouillette; Yin Wang; Yan Liu; Whitney Wright; Diane Roulston; Anjali Purkayastha; Amanda Dressel; Judith Karp; Paula Bockenstedt; Ammar Al-Zoubi; Moshe Talpaz; Lisa Kujawski; Yang Liu; Kerby Shedden; Sajid Shakhan; Cheng Li; Harry Erba; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-05-26       Impact factor: 12.531

6.  Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).

Authors:  Xian Zhang; Yantao He; Sijiu Liu; Zhihong Yu; Zhong-Xing Jiang; Zhenyun Yang; Yuanshu Dong; Sarah C Nabinger; Li Wu; Andrea M Gunawan; Lina Wang; Rebecca J Chan; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

7.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.

Authors:  Hideki Muramatsu; Hideki Makishima; Anna M Jankowska; Heather Cazzolli; Christine O'Keefe; Nao Yoshida; Yinyan Xu; Nobuhiro Nishio; Asahito Hama; Hiroshi Yagasaki; Yoshiyuki Takahashi; Koji Kato; Atsushi Manabe; Seiji Kojima; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 9.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

10.  Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.

Authors:  Xiaoqin Wu; Gang Xu; Xiaobo Li; Weiren Xu; Qianjin Li; Wei Liu; Karen A Kirby; Mignon L Loh; Jun Li; Stefan G Sarafianos; Cheng-Kui Qu
Journal:  J Med Chem       Date:  2018-12-05       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.